```html

Wegovy (Semaglutide) – Adverse Effects Guide

Overview

Wegovy® (semaglutide) is a once‑weekly injectable glucagon‑like peptide‑1 (GLP‑1) receptor agonist that has been approved by the U.S. Food and Drug Administration (FDA) for chronic weight management in adults with obesity (BMI ≥ 30 kg/m²) or overweight (BMI ≥ 27 kg/m²) with at least one weight‑related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia.

Semaglutide works by mimicking the natural hormone GLP‑1, which increases satiety, slows gastric emptying, and modestly reduces glucose production. While effective for weight loss—clinical trials report an average 15 % reduction in body weight after 68 weeks—its use is associated with a spectrum of adverse effects.

As of 2024, Wegovy has been prescribed to > 1 million patients in the United States, and worldwide sales exceed $2 billion, reflecting its rapid adoption. Understanding the possible side‑effects, their frequency, and how to manage them is essential for anyone taking this medication.

Symptoms

Adverse effects can be grouped into gastrointestinal, metabolic, musculoskeletal, psychiatric, and rare but serious categories. Frequency is reported from pivotal trials (STEP 1‑4) and post‑marketing surveillance.

Gastrointestinal (most common)

• Nausea – 30–45 % (usually mild, peaks during dose escalation)
• Vomiting – 15–20 % (often follows nausea)
• Diarrhea – 12–25 % (may be watery or loose)
• Constipation – 10–15 % (often after the first few months)
• Abdominal pain/discomfort – 8–12 %
• Indigestion (dyspepsia) – 5–10 %

Metabolic & endocrine

• Hypoglycemia – rare in non‑diabetic patients; more common (<5 %) in those on insulin or sulfonylureas
• Pancreatitis – reported in <0.1 % of users; presents with severe upper‑abdominal pain
• Gallbladder disease (biliary colic, cholelithiasis) – 1–2 % incidence, likely secondary to rapid weight loss
• Elevated serum lipase/amylase – usually asymptomatic, detected on routine labs

Renal

• Acute kidney injury (AKI) – reported in <0.5 % of patients, typically precipitated by dehydration from vomiting/diarrhea

Cardiovascular

• Increased heart rate (average +2‑4 bpm) – generally asymptomatic
• Hypotension – rare, may accompany volume depletion

Musculoskeletal & dermatologic

• Injection‑site reactions (redness, bruising, itching) – 5–10 %
• Joint pain (arthralgia) – 2–5 %
• Rash or urticaria – <1 %

Psychiatric & neurologic

• Headache – 10–15 %
• Dizziness – 5–8 %
• Depressed mood or anxiety – reported in <2 % (mostly anecdotal)

Rare but serious

• Medullary thyroid carcinoma (MTC) – theoretical risk; not observed in clinical trials but contraindicated in patients with personal/family history of MTC or multiple endocrine neoplasia type 2 (MEN 2) (FDA label)
• Severe allergic reaction (anaphylaxis) – <0.1 %

Causes and Risk Factors

Semaglutide’s mechanism (GLP‑1 receptor activation) explains most side‑effects. By slowing gastric emptying, it predisposes patients to nausea, vomiting, and constipation. The drug also influences gallbladder motility and bile composition, raising gallstone risk during rapid weight loss.

Key risk factors for developing adverse effects

• Rapid dose escalation – starting at the full maintenance dose (2.4 mg) increases GI intolerance.
• History of gastrointestinal disorders (e.g., gastroparesis, IBS) – higher likelihood of nausea and constipation.
• Concurrent use of other GLP‑1 agents or dipeptidyl‑peptidase‑4 (DPP‑4) inhibitors – additive GI effects.
• Use of insulin, sulfonylureas, or high‑dose fasting glucose‑lowering drugs – raises hypoglycemia risk.
• Dehydration or electrolyte imbalance – predisposes to AKI when vomiting/diarrhea occur.
• Personal or family history of thyroid C‑cell tumors – contraindication, not a cause but a safety concern.
• Pregnancy or breastfeeding – safety not established; may increase fetal exposure.

Diagnosis

Adverse effects are generally identified clinically, but structured assessment helps differentiate medication‑related issues from unrelated conditions.

Step‑by‑step evaluation

1. History – timing of symptom onset relative to dose changes, severity, diet, fluid intake, other medications.
2. Physical exam – focus on abdomen (tenderness, guarding), injection sites, vital signs (especially heart rate and blood pressure).
3. Laboratory tests (ordered based on symptoms):
   • Basic metabolic panel – evaluates electrolytes, renal function.
   • Serum lipase/amylase – screens for pancreatitis.
   • Liver function tests – rule out biliary obstruction.
   • Thyroid function (if indicated by family history).
4. Imaging when indicated:
   • Abdominal ultrasound – assesses gallbladder stones.
   • CT abdomen – for severe abdominal pain to exclude perforation or pancreatitis.
5. Medication review – check for drug interactions that may amplify gastrointestinal or hypoglycemic risks.

Treatment Options

Management focuses on symptom relief, dose adjustment, and, when needed, temporary discontinuation.

Pharmacologic measures

• Antiemetics – ondansetron or metoclopramide for persistent nausea/vomiting (short‑term use).
• Laxatives – osmotic agents (e.g., polyethylene glycol) for constipation; avoid stimulant laxatives unless needed.
• Antidiarrheals – loperamide for mild diarrhea; ensure no underlying infection.
• Proton pump inhibitors (PPIs) or H₂ blockers – for dyspepsia or reflux symptoms.
• Insulin/Oral hypoglycemic adjustment – reduce dose or temporarily hold agents that cause low blood sugar.

Non‑pharmacologic interventions

• Gradual dose titration – start at 0.25 mg weekly, increase every 4 weeks to the target 2.4 mg, per prescribing information.
• Dietary modifications – small, frequent meals; low‑fat, low‑fiber meals during titration; increase water intake.
• Hydration strategies – sip water throughout the day, especially if vomiting or diarrhea occurs.
• Physical activity – low‑impact exercise can aid bowel regularity and improve mood.
• Injection technique – rotate sites (abdomen, thigh, upper arm) to reduce local reactions.

When to pause or discontinue

Consider temporary hold if any of the following occur:

• Severe nausea/vomiting lasting > 48 hours
• Evidence of pancreatitis (persistent abdominal pain, lipase > 3× upper limit)
• Significant AKI (creatinine rise > 0.3 mg/dL)
• Confirmed gallbladder disease requiring surgery

Permanent discontinuation is recommended for diagnosed medullary thyroid carcinoma or confirmed hypersensitivity.

Living with Wegovy (semaglutide) adverse effects

Proactive self‑care can minimize discomfort and keep you on track with weight‑loss goals.

Daily management checklist

1. Take the injection on the same day each week. Set a reminder on your phone.
2. Monitor gastrointestinal symptoms. Keep a brief log of nausea severity (0‑10 scale), stool frequency, and any vomiting episodes.
3. Stay hydrated. Aim for ≥ 2 L of water daily; add electrolyte solutions if you have diarrhea.
4. Eat mindfully. Choose protein‑rich, low‑fat foods; avoid heavy or greasy meals during dose escalation.
5. Track weight and blood glucose (if diabetic). Sudden changes may signal side‑effects.
6. Review injection site. Look for redness, bruising, or swelling; rotate sites each week.
7. Plan for “breakthrough” nausea. Keep ondansetron (or a prescribed anti‑nausea) on hand.
8. Schedule follow‑up labs. Your clinician may order CMP, lipase, or thyroid labs every 3‑6 months.

Lifestyle tips

• Gentle yoga or walking after meals can improve gastric motility.
• Avoid alcohol and caffeine excess, which can exacerbate nausea and affect blood sugar.
• Consider a probiotic supplement (e.g., Lactobacillus rhamnosus) if constipation persists; discuss with your provider.
• Use a supportive pillow to sit upright for 30 minutes after the injection if you feel light‑headed.

Prevention

Many adverse effects can be prevented or lessened by adhering to best‑practice prescribing and patient‑education strategies.

Strategies before starting Wegovy

• Comprehensive medical history – screen for gallbladder disease, pancreatitis, thyroid cancer, and GI disorders.
• Baseline labs – CMP, lipase, HbA1c, and thyroid function tests.
• Patient education – explain the stepwise dose escalation and what to expect during the first 8‑12 weeks.

During therapy

• Follow the FDA‑approved titration schedule; avoid “jump‑starting” to the 2.4 mg dose.
• Implement a balanced, low‑fat diet from day 1.
• Stay consistent with hydration and physical activity.
• Report any severe GI symptoms to your clinician promptly.

Complications

If adverse effects are ignored or left untreated, they may lead to secondary health problems.

• Persistent vomiting or severe diarrhea → dehydration, electrolyte disturbances, and acute kidney injury.
• Chronic constipation → fecal impaction, hemorrhoids, or bowel obstruction.
• Undiagnosed pancreatitis → necrotizing pancreatitis, systemic inflammatory response, or chronic pancreatic insufficiency.
• Gallbladder disease → biliary colic, cholecystitis, or need for surgical removal, which can complicate future weight‑loss efforts.
• Hypoglycemia (in diabetic patients) → seizures, loss of consciousness, or accidents.
• Psychological distress – chronic nausea can affect mood, adherence, and overall quality of life.

When to Seek Emergency Care

References

• Mayo Clinic. Wegovy (semaglutide) – side effects and precautions. Link.
• U.S. Food and Drug Administration. Wegovy (semaglutide) Prescribing Information. Updated 2024.
• STEP 1–4 Clinical Trial Publications. New England Journal of Medicine, 2021‑2023.
• American Diabetes Association. Standards of Medical Care in Diabetes—2024. DOI.
• World Health Organization. Obesity and overweight fact sheet. 2023.
• Cleveland Clinic. Managing GLP‑1 gastrointestinal side effects. Link.
• CDC. Gallstone disease. 2022.

```